Skip to main content

Table 1 Clinicopathologic characteristics of diffuse large B cell lymphoma patients

From: Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma

Variables Full cohort (n = 51) R-CHOP cohort (n = 43)
Number of cases (%) Number of cases (%)
Age, years
 Mean (range) 59.6 (21–85)  
  < 60 21 (41%) 17 (40%)
  ≥ 60 30 (59%) 26 (60%)
Sex
 Male 30 (59%) 24 (56%)
 Female 21 (41%) 19 (44%)
Primary site
 Nodal 18 (35%) 14 (33%)
 Extranodal 33 (65%) 29 (67%)
Ann Arbor stage
 I, II 27 (53%) 23 (54%)
 III, IV 24 (37%) 20 (46%)
IPI groupa
 Low (0–2) 30 (60%) 27 (63%)
 High (3–5) 20 (40%) 16 (37%)
B symptomsa
 Absent 31 (62%) 29 (67%)
 Present 19 (38%) 14 (33%)
ECOG PSa
 0, 1 40 (82%) 37 (86%)
 ≥ 2 9 (18%) 6 (14%)
LDHa
 Normal 21 (42%) 19 (44%)
 Elevated 29 (58%) 24 (56%)
BM involvementa
 Absent 42 (91%) 38 (93%)
 Present 4 (9%) 3 (7%)
Number of extranodal sitesa
 0, 1 40 (80%) 33 (77%)
 ≥ 2 10 (20%) 10 (23%)
EBER
 Negative 40 (78%) 36 (84%)
 Positive 11 (22%) 7 (16%)
Hans classification
 GCB 14 (27%) 12 (28%)
 Non-GCB 37 (73%) 31 (72%)
Treatment
 Rituximab + CHOP 43 (84%) 43 (100%)
 Rituximab + others 1 (2%) 0 (0%)
 Surgery only 2 (4%) 0 (0%)
 No Tx 5 (10%) 0 (0%)
  1. IPI international prognostic index, ECOG PS Eastern Cooperative Oncology Group Performance Status, LDH lactate dehydrogenase, BM bone marrow, EBER EBV-encoded RNA, GCB germinal center B-like, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone
  2. aThese variables exclude missing values